Fierro-Arenas, A.Landskron, G.Camhi-Vainroj, I.Basterrechea, B.Parada-Venegas, D.Lobos-González, L.Dubois-Camacho, K.Araneda, C.Romero, C.Domínguez, A.Vásquez, G.López, F.Alvarez, K.González, C.Hager, C.Balboa, E.Eugenin, E.Hermoso, M.De la Fuente, M.2024-09-112024-09-112024-08Life Sciences, Volume 351 , 15 August 2024, 1228511879-0631https://repositorio.unab.cl/handle/ria/60124TEXTO COMPLETO EN ESPAÑOLAims Pannexin-1 (PANX1) is a hemichannel that releases ATP upon opening, initiating inflammation, cell proliferation, and migration. However, the role of PANX1 channels in colon cancer remains poorly understood, thus constituting the focus of this study. Main methods PANX1 mRNA expression was analyzed using multiple cancer databases. PANX1 protein expression and distribution were evaluated by immunohistochemistry on primary tumor tissue and non-tumor colonic mucosa from colon cancer patients. PANX1 inhibitors (probenecid or 10Panx) were used to assess colon cancer cell lines viability. To study the role of PANX1 in vivo, a subcutaneous xenograft model using HCT116 cells was performed in BALB/c NOD/SCID immunodeficient mice to evaluate tumor growth under PANX1 inhibition using probenecid. Key findings PANX1 mRNA was upregulated in colon cancer tissue compared to non-tumor colonic mucosa. Elevated PANX1 mRNA expression in tumors correlated with worse disease-free survival. PANX1 protein abundance was increased on tumor cells compared to epithelial cells in paired samples, in a cancer stage-dependent manner. In vitro and in vivo experiments indicated that blocking PANX1 reduced cell viability and tumor growth. Significance PANX1 can be used as a biomarker of colon cancer progression and blocking PANX1 channel opening could be used as a potential therapeutic strategy against this disease.esPANX1Colon cancerCancer progressionBiomarkerProbenecidTherapeutic targetingArtículohttps://doi.org/10.1016/j.lfs.2024.122851